Alerion Ventures

The Southeast US venture market has thickened considerably in the past decade, but most of the new capital arrived after the pandemic and concentrates in Atlanta, Nashville, and the Research Triangle. Alerion Ventures predates the surge. The Charleston, South Carolina firm has been operating as an evergreen vehicle since 2014, writing seed and Series A and Series B checks into B2B software companies, including healthcare software and tech-enabled services, across the Southeast. The firm’s positioning is that of a regional generalist with discipline rather than a vertical specialist with national ambitions, and its track record reflects steady deployment into companies most coastal firms would never see.

The thesis at Alerion centers on B2B software with operational substance. Healthcare exposure is concentrated in health IT and care delivery and tech-enabled services, areas where the firm’s geography offers genuine sourcing advantages. The Southeast hosts a meaningful share of the country’s hospital systems, ambulatory surgery operators, and health services businesses, and Alerion has used that proximity to back companies whose initial customers cluster regionally before scaling nationally. The firm’s evergreen structure shapes its investment cadence: rather than deploying a fund over a defined window, Alerion invests when the right opportunities arrive and reserves capital for follow-on across the full lifecycle of a portfolio company. Founders pitching consumer health, biotech, or deep clinical research will find the firm’s mandate too narrow. Founders building software or services for healthcare operators, with a Southeast US commercial wedge, will find a more natural conversation.

The specific portfolio composition is not enumerated in the source data, which means founders should plan to source comparable references directly through the firm during diligence. Alerion’s published material emphasizes patient-capital deployment into business-model-tested companies rather than narrative-driven early-stage bets. The firm tends to engage with companies that have at least early commercial traction and a defined buyer, even at the seed stage.

Check sizes fall in the one-to-five million dollar range, with the firm willing to participate from seed through Series B. That stage flexibility, combined with the evergreen structure, makes Alerion a useful partner for founders who would prefer not to recycle their cap table through multiple new lead investors at every stage. The firm leads selectively at seed and is comfortable as a meaningful participant at later stages. Founders raising rounds smaller than a million should look to angel capital or pre-seed funds; founders raising large growth rounds should expect Alerion to participate rather than to anchor.

Decision-making is concentrated within a small partner team in Charleston, which means the firm operates without committee theater. Founders engaged by Alerion meet decision-makers from the first conversation, and the diligence process is direct rather than layered. Pacing varies by stage and by the firm’s reserve position at any given moment, and founders should ask explicitly about timing during initial conversations.

The most effective approach is a warm introduction through a Southeast US founder or a regional banker familiar with the firm. Cold inbound is read but rarely prioritized. Founders should be prepared to discuss customer references and unit economics in concrete terms, even at seed, because the firm’s diligence emphasis tilts toward commercial substance over thematic positioning.

Founders should know that Alerion is a regional firm with regional advantages and regional limits. The firm is helpful on Southeast US customer introductions and operational hiring, less so on coastal venture syndication or national policy questions. Founders building healthcare software with a Southeast wedge will find Alerion a credible institutional anchor; founders pursuing national-from-day-one strategies should pair Alerion with at least one coastal co-investor.